 |
53 Diseases |  |
17 Trials |
|
17 Trials |  |
785 News |  |
| «12345678910111213...1415» |
- ||||||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Trial completion date: JPMS-CTEPH: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (clinicaltrials.gov) - Jan 29, 2024
P=N/A, N=1298, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Aug 2023
- ||||||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Enrollment change, Trial completion date: JPMS-PAH: Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jan 28, 2024
P=N/A, N=882, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Aug 2023 Recruiting --> Completed | N=600 --> 882 | Trial completion date: Jan 2024 --> Sep 2023
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Adempas (riociguat) / Bayer, Merck (MSD)
THE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY ON DIURETIC RESISTANT FLUID RETENTION IN A PATIENT WITH PULMONARY HYPERTENSION AND RIGHT HEART FAILURE (Moderated Poster Theater 10) - Jan 26, 2024 - Abstract #ACC2024ACC_4825;
With uptitration of Remodulin to a dose of 38 ng/kg/min at his 5/1/23 office visit, JS continued to struggle with significant fluid retention despite a furosemide 80 mg twice a day and metolazone 2.5 mg weekly regimen... In obese patients with PAH, GLP-1 RAs can be an effective therapeutic agent to enhance flesh weight loss, resulting in dramatic reversal of diuretic resistant fluid retention in right heart failure.
- Adempas (riociguat) / Bayer, Merck (MSD)
IMPACT OF BALLOON PULMONARY ANGIOPLASTY ON VENTILATORY INEFFICIENCY IN OPERABLE CTEPH - A CASE REPORT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4107;
However, he declined surgery and was unable to tolerate medical management with riociguat... In patients with proximal CTEPH, BPA can lead to improvement in ventilatory inefficiencies, which consequently improves symptoms and functional capacity.
- | Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, Merck (MSD), praliciguat (IW-1973) / Cyclerion
Retrospective data, Journal: Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction. (Pubmed Central) - Jan 24, 2024
In patients with proximal CTEPH, BPA can lead to improvement in ventilatory inefficiencies, which consequently improves symptoms and functional capacity. Vericiguat 10
- || Adempas (riociguat) / Bayer, Merck (MSD)
Review, Journal: Modulating NO-GC Pathway in Pulmonary Arterial Hypertension. (Pubmed Central) - Jan 15, 2024
PD5i are the recommended drugs for first-line PAH treatment, whereas sGCs are also the only drug approved for the treatment of resistant or inoperable chronic thromboembolic pulmonary hypertension. In this review, we will focus on the current information regarding the nitric oxide pathway and its modulation in PAH.
- Uptravi (selexipag) / J&J, Nippon Shinyaku
Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil (Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1719;
Notably, both these transitions occurred without invasive hemodynamic monitoring and were well tolerated with no hemodynamic compromise and only mild joint pain. Upon discharge, treprostinil was transitioned to subcutaneous administration per patient preference, with planned outpatient uptitration to goal dose based on hemodynamics and side effect profiles.Summary This approach outlines a safe 4-day transition from selexipag to IV treprostinil and challenges the need for concurrent invasive hemodynamic monitoring.
- Adempas (riociguat) / Bayer, Merck (MSD)
Enhancing Exercise Capacity in Exercise-Induced Pulmonary Hypertension: A Retrospective Study of Riociguat Therapy (Poster Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1346;
Although all the patients had an elevated exercise mPAP/CO slope of >3 mmHg, none had a PVR of 3 wood units. This highlights the importance of adopting the new ACC/AHA definition of Exercise PH (mPAP/CO >3 mmHg) to clinical practice.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers (clinicaltrials.gov) - Jan 5, 2024
P=N/A, N=15, Completed, Sponsor: Danish Headache Center
This highlights the importance of adopting the new ACC/AHA definition of Exercise PH (mPAP/CO >3 mmHg) to clinical practice. Recruiting --> Completed | Trial completion date: Jan 2024 --> Jun 2023 | Trial primary completion date: Jan 2024 --> Jun 2023
- || Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets (clinicaltrials.gov) - Dec 22, 2023
P1, N=36, Completed, Sponsor: Humanis Sagl?k Anonim Sirketi
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion date, Trial primary completion date: Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) (clinicaltrials.gov) - Nov 21, 2023
P2, N=22, Active, not recruiting, Sponsor: Bayer
Recruiting --> Completed | Trial completion date: Jan 2024 --> Jun 2023 | Trial primary completion date: Jan 2024 --> Jun 2023 Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- || Review, Journal: Pyrazole: an emerging privileged scaffold in drug discovery. (Pubmed Central) - Nov 15, 2023
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Some of the best-selling drugs in this class are ibrutinib, ruxolitinib, axitinib, niraparib
- || Adempas (riociguat) / Bayer, Merck (MSD)
Review, Journal: Chronic thromboembolic pulmonary hypertension-medical, interventional, and surgical therapy. (Pubmed Central) - Oct 22, 2023
In addition, interventional therapy is recommended if appropriate target lesions are proven. Evaluation and treatment of patients with CTEPH in experienced centers are mandatory.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion date, Trial primary completion date: REPO-STROKE II: Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE (clinicaltrials.gov) - Oct 19, 2023
P2, N=28, Recruiting, Sponsor: Maastricht University
Evaluation and treatment of patients with CTEPH in experienced centers are mandatory. Trial completion date: Jul 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Feb 2024
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion date, Trial primary completion date: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty (clinicaltrials.gov) - Sep 28, 2023
P2, N=20, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Jul 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Feb 2024 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- || Review, Journal: Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases. (Pubmed Central) - Sep 28, 2023
We aim to review the literature on recent advances in the treatment strategy and prognosis of patients with PAH-CTD. In this manuscript, we discuss the mechanism of action of PAH-specific drugs and new agents and the latest research conducted on PAH-CTD patients.
- Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3585;
This is the first meta-analysis on CTD-PAH that reported the pooled analysis of change in functional class, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have important prognostic value for PAH. Improvement in exercise capacity and reduction in risk of CW in CTD-PAH patients were less pronounced compared to idiopathic PAH (IPAH).
- A RARE CAUSE OF RIGHT HEART FAILURE: PULMONARY VENO-OCCLUSIVE DISEASE (Convention Center Exhibit Hall) - Sep 15, 2023 - Abstract #CHEST2023CHEST_6571;
- | Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J
Journal: Therapy With Inhaled Treprostinil, Macitentan, and Tadalafil/Riociguat in High-Risk Pulmonary Arterial Hypertension. (Pubmed Central) - Sep 15, 2023
Improvement in exercise capacity and reduction in risk of CW in CTD-PAH patients were less pronounced compared to idiopathic PAH (IPAH). No abstract available
- | Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, Merck (MSD)
Journal: Identification and characterization of the new generation sGC stimulator BAY 1165747 (BAY-747) designed for the treatment of resistant hypertension. (Pubmed Central) - Sep 7, 2023
BAY-747 shows long-acting pharmacodynamic effects with a very low peak-to-trough ratio. BAY-747 could be a treatment alternative for patients with hypertension, especially those not responding to standard-of-care therapy.
- | Adempas (riociguat) / Bayer, Merck (MSD), Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Preclinical, Journal: The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices. (Pubmed Central) - Sep 2, 2023
Vasodilation to Cmpd17b, but not standard-of-care vasodilators, is maintained under inflammatory conditions, with additional inhibition of PAH-relevant cytokine release. Our study provides the first evidence that targeting FPR, using a biased agonist, simultaneously targets vascular function and inflammation, supporting the development of FPR-based pharmacotherapy to treat PAH.
- || Adempas (riociguat) / Bayer, Merck (MSD)
Review, Journal: Emerging Role of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease-Insights from the 2022 ESC Guidelines. (Pubmed Central) - Aug 26, 2023
Patients who received pre-treatment with riociguat prior to BPA exhibited a notable reduction in the occurrence of less severe complications...The 2022 ESC/ERS guidelines highlight the significant role of BPA in the multimodal treatment of CTEPH, emphasizing its effectiveness and recommending its consideration as a therapeutic option for patients with CTEPD, both with and without pulmonary hypertension. This review summarizes the available evidence for BPA, patient selection, procedural details, and prognosis and discusses the potential future role of BPA in the management of CTEPH.
- | Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment open: PHoenix: Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (clinicaltrials.gov) - Aug 22, 2023
P4, N=40, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
This review summarizes the available evidence for BPA, patient selection, procedural details, and prognosis and discusses the potential future role of BPA in the management of CTEPH. Not yet recruiting --> Recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD), cinaciguat (BAY 58-2667) / Bayer
Preclinical, Journal: Hydrogen sulfide regulates the redox state of soluble guanylate cyclase in CSE mice corpus cavernosum microcirculation. (Pubmed Central) - Aug 21, 2023
In conclusion, the endogenous CSE-derived HS plays a physiological key role in the regulation of the redox state of sGC in CC microcirculation. DATA AVAILABILITY: Data are contained within the article or supplementary material.
- || Adempas (riociguat) / Bayer, Merck (MSD), praliciguat (IW-1973) / Cyclerion
Review, Journal: Recent developments in targets for ischemic foot disease. (Pubmed Central) - Aug 11, 2023
In conclusion, an ever-expanding list of potential targets for medical revascularisation is being identified. It is hoped that through ongoing research and further larger clinical trials, these will translate into new broadly applicable therapies to improve outcomes.
- EFFECTIVENESS OF A VIRTUAL PATIENT SIMULATION AT IMPROVING MANAGEMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_4254;
- UNCOMMON BUT NOT UNSEEN: A RARE CAUSE OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3493;
- WHEN PRECAPILLARY PULMONARY HYPERTENSION OCCURS POST-LUNG TRANSPLANTATION (Convention Center Exhibit Hall - Rapid Area 4D) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2890;
- MULTIDISCIPLINARY MANAGEMENT OF A RARE CASE: DISSEMINATED ECHINOCOCCUS HYDATID DISEASE WITH PULMONARY EMBOLISM AND HYPERTENSION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2498;
- COMPLETE RIGHT PULMONARY ARTERY OBSTRUCTION MIMICKING A RIGHT HILAR TUMOR (Convention Center Exhibit Hall - Rapid Area 4C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2485;
- A CASE OF POST-SPLENECTOMY PULMONARY HYPERTENSION (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1630;
- CHRONIC THROMBOEMBOLIC DISEASE DUE TO ANTIPHOSPHOLIPID DISEASE COMPLICATED BY ACUTE LYMPHOPROLIFERATIVE DISEASE: A CASE REPORT (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_1584;
- | Adempas (riociguat) / Bayer, Merck (MSD)
Journal: Refined Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: Initial Results of U.S. Regional Program. (Pubmed Central) - Jul 28, 2023
The independent factors associated with a improved functional and hemodynamic response included the pre-procedural use of riociguat, reduce baseline PA compliance and > 3 BPA sessions per patient. This single center study from the US showed that BPA with refined techniques in patients with CTEPH was safe and was associated with significant improvements in pulmonary hemodynamics and functional capacity.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases (clinicaltrials.gov) - Jul 20, 2023
P2, N=130, Completed, Sponsor: Mark Gladwin
This single center study from the US showed that BPA with refined techniques in patients with CTEPH was safe and was associated with significant improvements in pulmonary hemodynamics and functional capacity. N=97 --> 130
- || Review, Journal: The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report. (Pubmed Central) - Jul 14, 2023
N=97 --> 130 The biannual international cGMP conference, launched nearly 20
- | Tysabri (natalizumab) / Biogen, Royalty, Adempas (riociguat) / Bayer, Merck (MSD)
Journal: Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. (Pubmed Central) - Jul 10, 2023
The biannual international cGMP conference, launched nearly 20 Physicians are generally aware of ETASU REMS and get reassurance from the additional oversight, but the programs can be better integrated into clinical workflows and can be designed to better protect patient health information.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Journal, Claims database: Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study. (Pubmed Central) - Jul 3, 2023
Physicians are generally aware of ETASU REMS and get reassurance from the additional oversight, but the programs can be better integrated into clinical workflows and can be designed to better protect patient health information. Overall, we identified 407 women with ?
- | Adempas (riociguat) / Bayer, Merck (MSD), cinaciguat (BAY 58-2667) / Bayer
Journal: Effects of Soluble Guanylate Cyclase Stimulators and Activators on Anti-Aggregatory Signalling in Patients with Coronary Artery Spasm. (Pubmed Central) - Jun 14, 2023
However, the intrinsic anti-aggregatory effects of CINA are most marked in individuals with initially normal NO/sGC signalling, and thus their magnitude is at variance with extent of physiological impairment. These data suggest that RIO and other sGC stimulators should be evaluated for clinical utility in both prophylaxis and treatment of CAS.
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: ROAR: A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (clinicaltrials.gov) - Jun 2, 2023
P=N/A, N=500, Recruiting, Sponsor: Bayer
These data suggest that RIO and other sGC stimulators should be evaluated for clinical utility in both prophylaxis and treatment of CAS. Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
- | Adempas (riociguat) / Bayer, Merck (MSD)
First case of the Month on NeoCardioLab by @CMichelK - Riociguat in a case oh infantile PH. https://t.co/W3Aw93BiBw @NeoHemodynamics @NeoHeartSociety @PVRI @PPHNet @PulmonaryNews @PHAssociation (Twitter) - May 31, 2023
- Adempas (riociguat) / Bayer, Merck (MSD)
Risk assessment according to the presence of left heart disease phenotype in pulmonary arterial hypertension patients: a multicenter cohort study. (Science Box 3) - May 13, 2023 - Abstract #ESC2023ESC_3648;
This study suggests that the performance of risk stratification scores COMPERA and COMPERA 2.0 in PAH subjects with a LHD phenotype is limited, although the former may retain value during follow-up. Alternative tools may be needed for prognostication in this patient subset.
- Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J
PAH-specific treatment for patients with combined pre- and post-capillary pulmonary hypertension (Science Box 3) - May 13, 2023 - Abstract #ESC2023ESC_3646;
Conclusions In patients suffering from Cpc-PH, PAH-specific therapy leads to improvement of symptoms. Further studies are required to extend this finding to a larger patient group to assess whether PAH-specific drugs may also improve hemodynamics, right ventricular function and mortality.
- Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J, Nippon Shinyaku
Hemodynamic changes with pulmonary arterial hypertension targeted therapies: a meta-analysis of 3898 treatment-naive patients (Vilnius; Online) - May 13, 2023 - Abstract #ESC2023ESC_2742;
Further studies are required to extend this finding to a larger patient group to assess whether PAH-specific drugs may also improve hemodynamics, right ventricular function and mortality. or p.o./inh], riociguat, and selexipag) either in monotherapy or combinations as assessed by right heart catheterization (RHC) in treatment-na
- Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, Merck (MSD), praliciguat (IW-1973) / Cyclerion
Soluble guanylate cyclase in heart failure: A network meta-analysis and subgroup analyses of reduced and preserved ejection fraction. (Station 3) - May 13, 2023 - Abstract #ESC2023ESC_1273;
Therefore, our data regarding other agents (riociguat and praliciguat) and HFpEF can be underpowered. This warrants further RCTs to clarify vericiguat 10 mg place in HFrEF management guidelines and to investigate sGC stimulators for HFpEF in large-scale adequately designed trials.
- Adempas (riociguat) / Bayer, Merck (MSD)
Riociguat: mechanism of action and efficacy in patients with pulmonary arterial hypertension (Riga) - May 13, 2023 - Abstract #ESC2023ESC_105;
- | Adempas (riociguat) / Bayer, Merck (MSD)
Journal: The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression. (Pubmed Central) - May 8, 2023
The combined effects on ROS and hepatocyte apoptosis attenuated the stimulation of HSC activation and ECM deposition in a mouse model of liver fibrosis. This work provides a novel strategy for liver fibrosis treatment based on sinusoidal perfusion enhancement and apoptosis inhibition.
- | Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J, Nippon Shinyaku
New P4 trial: PHoenix: Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (clinicaltrials.gov) - Apr 24, 2023
P4, N=40, Not yet recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
- || Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed: JPMS-CTEPH: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (clinicaltrials.gov) - Apr 21, 2023
P=N/A, N=1298, Active, not recruiting, Sponsor: Bayer
This work provides a novel strategy for liver fibrosis treatment based on sinusoidal perfusion enhancement and apoptosis inhibition. Recruiting --> Active, not recruiting
- ||| Adempas (riociguat) / Bayer, Merck (MSD)
Riociguat benefits Pul Hypertension Its sister drug should have some effect on PH secondary to LHF or secondary functional MR Any such substudy (Twitter) - Apr 4, 2023